Peak Pharma Reports Initial Canna-Pet Revenue with 72.7% Gross Margin

Peak Pharmaceuticals Inc. [stockquote symbol=PKPH], the leading innovator of over-the-counter cannabinoid products for animals and manufacturer of Canna-Pet™ pet health products, achieved a significant milestone recently with the release of their first quarter fiscal 2015 business update. The company has clearly made the leap from development to “growth stage” status on news of  $161,360 in revenues with nearly 73% gross margins in their latest 10-Q filing from February 17th.   With a solid management team in place led by Dr. Soren Mogelsvang, Peak Pharmaceuticals has proven an ability to provide a short-term path to commercialization in a highly scalable business model.  In this article we will be interviewing Dr. Mogelsvang, and looking further into the upcoming potential of Peak Pharmaceuticals.

Peak Pharmaceuticals began developing, manufacturing, and marketing pharmaceutical-grade phytocannabinoid products for the prevention and treatment of various diseases in March of 2014. Since then, the company has entered into a licensing agreement with Canna-Pet™, signed a cultivation agreement with a Colorado-based hemp farm, and rebranded itself to better reflect its position in the growing hemp market.

The fruits of these efforts have started to show up in its fourth quarter 2014 financial results, which included initial revenue from its CBD-infused Canna-Pet™ pet health products. The company generated $161,360 in revenue, between processing the first order on October 16, 2014 and December 31st, 2014.  That works out to an average sales volume of just over $2,100 per day, and with management recently indicating that they’ve seen strong growth in order volumes during the first quarter of 2015, investors may want to add Peak Pharmaceuticals to their watch list.

Embed Vimeo Interview below:

Potential Profitability

Peak Pharmaceuticals could break even on the bottom-line with attainable sales of $4.37 million per year, assuming a steady 73% gross margin and stable expenses. It’s worth noting that more than 70% of its SG&A last quarter was in the form of equity-based compensation, which are a type of “in-kind” expense that differs from traditional expenses. By discounting these expenses, the company appears to be rapidly approaching a break-even point.

The high gross margins also point to high-growth potential over the long-term. Each dollar generated in sales past the break even level will drop down $0.73 to the bottom-line. These dynamics suggest that the company could be highly profitable over the long-term as it grows revenue past expenses. At the same time, the attractive gross margins provide management with added flexibility in pursuing other ventures without resorting to dilution.

Management’s long-term focus on profitability is highlighted by its hemp cultivation agreement, which should provide lower cost inputs for its current and future CBD-infused products. By keeping these raw materials costs down, the company can lower both its fixed R&D expenses and variable production expenses. The lower expenses frees up cash flow for the company’s future endeavors and ultimately enhances long-term shareholder value.

Long-term Potential

Non-psychoactive hemp-based foods have been fully legalized following a February 2004 court decision – HIA v. DEA – where a judge ruled that the DEA could not regulate naturally occurring THC not contained within or derived from a marijuana plant. With hemp-based CBDs excluded from the DEA’s Schedule I Controlled Substances list, anybody is free to sell non-psychoactive hemp-based nutritional supplements or other food-based products.

The recession-proof U.S. pet industry grew at an 8% CAGR to reach $51.58 billion in 2014, according to the American Pet Products Association, creating a large initial market for Peak Pharmaceuticals’ hemp-based CBD-infused Canna-Pet™ products. Companies in the industry such as PetSmart Inc. (NASDAQ: PETM) and VCA Inc. (NASDAQ: WOOF) have seen their stock prices appreciate by more than 10% in the last 3 months alone, a reflection of this impressive growth trend.

The Pet Supply and OTC medication industries make up $14 billion and $13.72 billion, respectively, of the overall $51.58 billion pet industry.  The $14 billion Pet Supply industry is a particularly strong market segment, as 41% of pet owners have considered or tried various alternative therapies. Peak Pharmaceuticals Canna-Pet™ products fall into this category, showing an existing, large market prime for capture.

While pets represent a low-hanging fruit and a short-term path to revenues, the company ultimately plans on expanding it’s market potential by offering hemp-based CBD-infused products to humans, which management plans to introduce later this year. While companies such as GW Pharmaceuticals plc (NASDAQ: GWPH) are making great strides in the clinical trial world, their approach endures a lengthier time frame to commercialization than a company like Peak Pharmaceuticals, as FDA studies are both lengthy and necessary.

Looking Ahead

Peak Pharmaceuticals stands at a tipping point with early signs of revenue providing validation of its highly scalable business model. With indications of top-line growth in early 2015, the company is on its way toward breaking even on a bottom-line basis. Management is also gearing up for the release of its first human-targeted products later this year, which could further catalyze the stock over the coming quarters.

For more information, visit the company’s website at www.peakpharma.com.

To sign up for future email updates, please visit: http://www.tdmfinancial.com/emailassets/pkph/pkph_landing.php

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Disclaimer: Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. Emerging Growth LLC dba TDM Financial, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Search CannabisFN

Press Coverage

Psychedelics Index

Top Videos

Michael Berger of Technical 420

Technical420 is the premier provider of research and analysis on cannabis stocks.  We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry.  “Our research is our passion!”  Your profit is our reward!

Neill Dixon of O’Cannabiz Conference & Expo

The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.

Pure Extracts Corp.

Pure Extracts is positioned to be the dominant extraction company to rapidly develop and commercialize functional and psychedelic medicine.

Flora Growth Corp.

Flora is building a connected, design-led collective, of plant-based wellness and lifestyle brands, that delivers the most compelling customer experiences in the world, one community at a time.

Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer